Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo
Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
- no estimate extracted1 study · 20 participantsLow
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).